Last reviewed · How we verify
Infanrix TM
Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens.
Infanrix is a combination vaccine that stimulates the immune system to produce antibodies against diphtheria, tetanus, and pertussis (whooping cough) pathogens. Used for Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters).
At a glance
| Generic name | Infanrix TM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Infanrix contains inactivated toxoids of diphtheria and tetanus, along with acellular pertussis antigens, which trigger adaptive immune responses without causing disease. The vaccine primes both humoral (antibody) and cellular immunity to protect against these three bacterial infections. It is administered as part of the primary childhood immunization series to establish protective immunity before natural exposure.
Approved indications
- Prevention of diphtheria, tetanus, and pertussis in infants and children (primary series and boosters)
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
- Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults (PHASE2)
- Study to Evaluate the Safety of Co-administration of GSK Biologicals' Poliorix and Infanrix in Healthy Children in Russia (PHASE4)
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age (PHASE3)
- Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents (PHASE4)
- Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects (PHASE3)
- Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects (PHASE3)
- Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. (PHASE3)
- Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infanrix TM CI brief — competitive landscape report
- Infanrix TM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI